Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating Expenses:
Research and development	$ 13,067	$ 17,576
In-process research and development	30,393	0
General and administrative	14,141	11,474
Operating expenses	57,601	29,050
Operating loss	(57,601)	(29,050)
Other income (expense):
Investment income, net	1,052	151
Other expense, net	(155)	(75)
Total other income	897	76
Net loss before benefit from income taxes and noncontrolling interests	(56,704)	(28,974)
Benefit from income taxes	(2,479)	(1,508)
Net loss	(54,225)	(27,466)
Less - net income (loss) attributable to noncontrolling interests	0	0
Net loss attributable to Lisata Therapeutics, Inc. common stockholders	$ (54,225)	$ (27,466)
Basic and diluted loss per share:
Lisata Therapeutics, Inc. common stockholders - basic (in dollars per share)	$ (10.47)	$ (7.45)
Lisata Therapeutics, Inc. common stockholders - diluted (in dollars per share)	$ (10.47)	$ (7.45)
Weighted average common shares outstanding:
Basic shares	5,180	3,688
Diluted shares	5,180	3,688